Kanan Patel1, Gregg C Fonarow1, Momanna Ahmed1, Charity Morgan1, Meredith Kilgore1, Thomas E Love1, Prakash Deedwania1, Wilbert S Aronow1, Stefan D Anker1, Ali Ahmed2. 1. From the Department of Medicine, University of California, San Francisco (K.P.); Division of Cardiology, University of California, Los Angeles (G.C.F.); Comprehensive Center for Healthy Aging (M.A.), Department of Biostatistics (C.M.) and Department of Health Care Organization and Policy (M.K.), School of Public Health, University of Alabama at Birmingham (M.A., C.M., M.K.); Department of Medicine, Case Western Reserve University, Cleveland, OH (T.E.L.); Department of Medicine, University of California, San Francisco, Fresno (P.D.); Department of Medicine, New York Medical College, Valhalla, NY (W.S.A.); Department of Innovative Clinical Trials, University Medical Centre Göttingen, Göttingen, Germany (S.D.A.); Center for Health and Aging, Veterans Affairs Medical Center, Washington, DC (A.A.). 2. From the Department of Medicine, University of California, San Francisco (K.P.); Division of Cardiology, University of California, Los Angeles (G.C.F.); Comprehensive Center for Healthy Aging (M.A.), Department of Biostatistics (C.M.) and Department of Health Care Organization and Policy (M.K.), School of Public Health, University of Alabama at Birmingham (M.A., C.M., M.K.); Department of Medicine, Case Western Reserve University, Cleveland, OH (T.E.L.); Department of Medicine, University of California, San Francisco, Fresno (P.D.); Department of Medicine, New York Medical College, Valhalla, NY (W.S.A.); Department of Innovative Clinical Trials, University Medical Centre Göttingen, Göttingen, Germany (S.D.A.); Center for Health and Aging, Veterans Affairs Medical Center, Washington, DC (A.A.). aliahmedmdmph@gmail.com.
Abstract
BACKGROUND: Little is known about associations of calcium channel blockers (CCBs) with outcomes in patients with heart failure and preserved ejection fraction (EF). METHODS AND RESULTS: Of the 10 570 hospitalized patients with heart failure and preserved EF, ≥65 years, EF ≥40%, in the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF; 2003-2004), linked to Medicare data (through December 31, 2008), 7514 had no prior history of CCB use. Of these, 815 (11%) patients received new discharge prescriptions for CCBs. Propensity scores for CCB initiation, calculated for each of the 7514 patients, were used to assemble a matched cohort of 1620 (810 pairs) patients (mean age, 80 years; mean EF, 56%; 65% women; 10% black) receiving and not receiving CCBs, balanced on 114 baseline characteristics. The primary composite end point of all-cause mortality or heart failure hospitalization occurred in 82% and 81% of patients receiving and not receiving CCBs (hazard ratio for CCBs, 1.03; 95% confidence interval, 0.92-1.14). Hazard ratios (95% confidence intervals) for all-cause mortality, heart failure hospitalization, and all-cause hospitalization were 1.05 (0.94-1.18), 1.05 (0.91-1.21), and 1.03 (0.93-1.14), respectively. Similar associations were observed when we categorized patients into those receiving amlodipine and nonamlodipine CCBs. Among 7514 prematch patients, multivariable-adjusted and propensity-adjusted hazard ratios (95% confidence interval) for primary composite end point were 1.03 (0.95-1.12) and 1.02 (0.94-1.11), respectively. CONCLUSIONS: In hospitalized older patients with heart failure, new discharge prescriptions for CCBs had no associations with composite or individual end points of mortality or heart failure hospitalization, regardless of the class of CCBs.
BACKGROUND: Little is known about associations of calcium channel blockers (CCBs) with outcomes in patients with heart failure and preserved ejection fraction (EF). METHODS AND RESULTS: Of the 10 570 hospitalized patients with heart failure and preserved EF, ≥65 years, EF ≥40%, in the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF; 2003-2004), linked to Medicare data (through December 31, 2008), 7514 had no prior history of CCB use. Of these, 815 (11%) patients received new discharge prescriptions for CCBs. Propensity scores for CCB initiation, calculated for each of the 7514 patients, were used to assemble a matched cohort of 1620 (810 pairs) patients (mean age, 80 years; mean EF, 56%; 65% women; 10% black) receiving and not receiving CCBs, balanced on 114 baseline characteristics. The primary composite end point of all-cause mortality or heart failure hospitalization occurred in 82% and 81% of patients receiving and not receiving CCBs (hazard ratio for CCBs, 1.03; 95% confidence interval, 0.92-1.14). Hazard ratios (95% confidence intervals) for all-cause mortality, heart failure hospitalization, and all-cause hospitalization were 1.05 (0.94-1.18), 1.05 (0.91-1.21), and 1.03 (0.93-1.14), respectively. Similar associations were observed when we categorized patients into those receiving amlodipine and nonamlodipine CCBs. Among 7514 prematch patients, multivariable-adjusted and propensity-adjusted hazard ratios (95% confidence interval) for primary composite end point were 1.03 (0.95-1.12) and 1.02 (0.94-1.11), respectively. CONCLUSIONS: In hospitalized older patients with heart failure, new discharge prescriptions for CCBs had no associations with composite or individual end points of mortality or heart failure hospitalization, regardless of the class of CCBs.
Authors: Jason L Guichard; Ravi V Desai; Mustafa I Ahmed; Marjan Mujib; Gregg C Fonarow; Margaret A Feller; O James Ekundayo; Vera Bittner; Inmaculada B Aban; Michel White; Wilbert S Aronow; Thomas E Love; George L Bakris; Susan J Zieman; Ali Ahmed Journal: Hypertension Date: 2011-09-26 Impact factor: 10.190
Authors: Kanan Patel; Gregg C Fonarow; Dalane W Kitzman; Inmaculada B Aban; Thomas E Love; Richard M Allman; Mihai Gheorghiade; Ali Ahmed Journal: Eur J Heart Fail Date: 2012-07-03 Impact factor: 15.534
Authors: Prakash C Deedwania; Mustafa I Ahmed; Margaret A Feller; Inmaculada B Aban; Thomas E Love; Bertram Pitt; Ali Ahmed Journal: Eur J Heart Fail Date: 2011-03-09 Impact factor: 15.534
Authors: M Packer; C M O'Connor; J K Ghali; M L Pressler; P E Carson; R N Belkin; A B Miller; G W Neuberg; D Frid; J H Wertheimer; A B Cropp; D L DeMets Journal: N Engl J Med Date: 1996-10-10 Impact factor: 91.245
Authors: Kanan Patel; Gregg C Fonarow; Dalane W Kitzman; Inmaculada B Aban; Thomas E Love; Richard M Allman; Mihai Gheorghiade; Ali Ahmed Journal: JACC Heart Fail Date: 2013-02 Impact factor: 12.035
Authors: Carsten Tschöpe; Christoph Birner; Michael Böhm; Oliver Bruder; Stefan Frantz; Andreas Luchner; Lars Maier; Stefan Störk; Behrouz Kherad; Ulrich Laufs Journal: Clin Res Cardiol Date: 2017-10-10 Impact factor: 5.460
Authors: Zhenyu Hu; Jiong-Wei Wang; Dejie Yu; Jia Lin Soon; Dominique P V de Kleijn; Roger Foo; Ping Liao; Henry M Colecraft; Tuck Wah Soong Journal: Sci Rep Date: 2016-10-12 Impact factor: 4.379
Authors: Phillip H Lam; Daniel J Dooley; Prakash Deedwania; Steven N Singh; Deepak L Bhatt; Charity J Morgan; Javed Butler; Selma F Mohammed; Wen-Chih Wu; Gurusher Panjrath; Michael R Zile; Michel White; Cherinne Arundel; Thomas E Love; Marc R Blackman; Richard M Allman; Wilbert S Aronow; Stefan D Anker; Gregg C Fonarow; Ali Ahmed Journal: J Am Coll Cardiol Date: 2017-10-10 Impact factor: 24.094
Authors: Andrew H Coles; Mayra Tisminetzky; Jorge Yarzebski; Darleen Lessard; Joel M Gore; Chad E Darling; Robert J Goldberg Journal: J Am Heart Assoc Date: 2015-12-23 Impact factor: 5.501